July 15, 2005 — The U.S. Food and Drug Administration (FDA) has approved single- and dual-chamber versions of an implantable cardioverter defibrillator that feature managed ventricular pacing and ...
The GORE VIABAHN Endoprosthesis portfolio spans a wide variety of sizes, including the recently added 7.5 cm and 25 cm length versions, the industry’s longest such device. The dynamic range of options ...
The investigational device evaluated in the trial, previously known as the GORE ® VIAFORT Vascular Stent, will now be referred to as the GORE ® VIABAHN ® FORTEGRA Venous Stent. CAUTION: ...
Gore won FDA approval for its VIABAHN VBX endoprosthesis to be used in the iliac arteries, making it the only balloon expandable stent graft having such an indication. It can be used on new or ...
FLAGSTAFF, Ariz., W. L. Gore & Associates (Gore) announces that the first patients are now enrolled in the Gore RELINE MAX Clinical Study, a post-approval study to continue to evaluate the GORE® ...
Improvements to large diameter devices include accessibility through smaller sheaths while providing enhanced visualization by adding radiopaque markers 25 years of continued innovation PUTZBRUNN, ...
The GORE® VIABAHN® FORTEGRA Venous Stent is engineered to offer an optimal balance of conformability and compression resistance for treating a broad range of patients. FLAGSTAFF, Ariz., Jan. 6, 2026 ...
(MENAFN- PR Newswire) The Gore VBX FORWARD Clinical Study aims to compare the VBX Stent Graft primary patency to bare metal stenting to evaluate superiority in treating complex iliac occlusive disease ...
The EMBRACE Registry aims to evaluate safety and performance of the GORE ® VIABAHN ® VBX Balloon Expandable Endoprosthesis when used as a bridging stent with branched and fenestrated endografts in the ...
FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) is celebrating the 20 th anniversary of the introduction of the GORE® VIABAHN® Endoprosthesis, the market-leading stent-graft ...
The GORE VIABAHN Endoprosthesis is backed by an ever-growing body of clinical data, including nine randomized or prospective multicenter studies. This continued device evolution and extensive body of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results